Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

Lundbeck

Status and phase

Terminated

Phase 2

Conditions

Bipolar Disorder

Treatments

Drug: Quetiapine

Drug: Placebo

Drug: Lu AA39959

Study type

Interventional

Funder types

Industry

Identifiers

NCT00771134

12601A

Details and patient eligibility

About

This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.

Full description

Bipolar disorder is a common lifelong psychiatric disorder characterized by recurrent mood swings with manic or hypomanic episodes alternated with depressive episodes of longer duration. Patients spend more time in depression than in (hypo)mania over their life time. The main goals for the treatment of bipolar disorder are resolution of symptoms, return to premorbid level of social functioning and prevention of future episodes.

Although there are many treatments for bipolar disorder, few are approved, and they have limitations in their use due to safety and tolerability issues. Recommendations exist to use mood stabilisers, antipsychotics or a combination thereof with or without antidepressants and the polypharmacy employed in many cases is a reason for concern. There is a major medical need for more effective treatments in monotherapy with a reduced potential for adverse effects. This study evaluates the efficacy and safety of the new drug, Lu AA39959, in treatment of depression in patients with bipolar disorder.

Enrollment

105 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Patients suffering from a major depressive episode of bipolar II or I disorder, according to DSM-IV TR

Inclusion Criteria:

Current major depressive episode of bipolar II or I disorder, according to DSM-IV TR
Moderate to severe depression
History of at least one documented mania or hypomania episode
Absence of current mania or hypomania

Exclusion Criteria:

Any current psychiatric disorder other than bipolar disorder defined in the DSM-IV TR
Any substance disorder with the previous 6 months
Use of any psychoactive medication (including mood stabilizers) within 2 weeks before randomisation and during the study
ECT within 6 months before the study
Female of childbearing potential and not using adequate contraception
Other protocol-defined inclusion and exclusion criteria may apply